Treatment Persistence and Outcomes in Pediatric Tourette Syndrome Patients, 2011-2021

A retrospective cohort study of 1,684 pediatric patients with Tourette syndrome compares adverse events and healthcare resource utilization between those newly treated with dopamine D2 receptor modulators and a non-exposed cohort. Data were analyzed from the TriNetX Dataworks-USA Network electronic health records database covering over 119 million individuals from 2011 to 2021. The study, authored by Kinga K. Tomczak, was posted on figshare in 2026.

Use Cases

• Analyzing treatment persistence patterns based on documented monthly medication record declines.
• Comparing odds of mild, moderate, and severe adverse events between exposed and non-exposed cohorts.
• Evaluating differences in all-cause and TS-related healthcare resource utilization rates.
• Studying real-world prescribing and monitoring patterns for antipsychotics in a pediatric population.

Strengths

• Exact-matched cohorts of 1,684 individuals each provide a balanced comparison.
• Analysis spans a 10-year period (2011-2021) from a large EHR network covering over 119 million individuals.
• Study reports specific odds ratios and incidence rate ratios for adverse events and healthcare utilization.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying data is unknown, which may limit suitability assessment.
• The authors note findings are associational and may reflect residual confounding, differential monitoring, or underlying disease severity.

Provenance

Source

TriNetX Dataworks-USA Network electronic health records database.

Collection Method

Retrospective analysis of EHR data.

Time Range

2011 to 2021.

Freshness

Last updated 2026-06-02 11:10:54; freshness should be verified.

Geography

United States (likely, based on data source).